

Technology for the future Diagnosis and Beyond

Company	Amlu Biosciences Ltd	Established	2017
Entity	Spin-out company of the University of Newcastle-Upon-Tyne	Location	Newcastle Upon-Tyne, UK
		Industry	Bio / Pharma
		Specialism	Diagnostics

The challenge

Expert IP advice was required to ensure the development of a robust IP portfolio for the firm which would enable future commercialisation and investment if required, as well as future proofing their patents against competitors.

The solution

The extensive experience within the Secerna team ensured that we understood the changing requirements of the firm and could help them manage their IP portfolio and budgets. This meant understanding the complex science dealing with metastatic melanoma. The company was spun out within three years from first filing, and European patents granted in the same timescale. This enabled our client to focus on growing the business.



How we added value

The Secerna team invested time to understand the business, and its goals and aims. Our expertise in this area also allowed us to provide a robust strategy and filing programme and to help our client manage resources during their set up and in particular protect their product AMBLor®. This has resulted in the patent family being acknowledged as important in various due diligences performed on the company.

“Charlotte and her team really understood the technology and the issues we faced, this understanding helped us in developing a robust filing strategy which has reaped rewards as we have grown. They showed great insight and foresight into our technology and industry.” **Marie Labus | CEO**



SECERNA
IP SPECIALISTS

For more information or an informal chat please call us on:
+44 (0)1904 202 900 or email us: docketing@secerna.co.uk

www.secerna.co.uk